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Abstract In order to provide a common standard for the treatment of mycosis fungoides
(MF) and Se´zary syndrome (SS), the European Organisation for Research and Treatment
of CancereCutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its
consensus recommendations for the stage-adapted selection of management options for these
neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS
has advanced, the staging system has been revised, new outcome data have been published and
novel treatment options have been introduced. The purpose of the present document is to up-
date the original recommendations bearing in mind that there are still only a limited number of
controlled studies to support treatment decisions for MF/SS and that often treatment is deter-
mined by institutional experience and availability.
This consensus on treatment recommendations was established among the authors through
a series of consecutive consultations in writing and a round of discussion. Recommended
treatment options are presented according to disease stage, whenever possible categorised into
first- and second-line options and supported with levels of evidence as devised by the Oxford
Centre for Evidence-Based Medicine (OCEBM).
Skin-directed therapies are still the most appropriate option for early-stage MF, and most
patients can look forward to a normal life expectancy. For patients with advanced disease,
prognosis is still grim, and only for a highly selected subset of patients, prolonged survival
can be achieved with allogeneic stem cell transplantation (alloSCT). There is a high need
for the development and investigation in controlled clinical trials of treatment options that
are based on our increasing understanding of the molecular pathology of MF/SS.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cutaneous T-cell lymphomas (CTCLs) are a group of
rare non-Hodgkin lymphomas (NHLs) characterised by
initial localisation of malignant T-lymphocytes to the
skin. Current definition of these neoplasms follows the
2016 revision of the World Health Organisation (WHO)
classification of tumours of haematopoietic and
lymphoid tissues that largely incorporates the WHO-
EORTC classification for cutaneous lymphomas pub-
lished in 2005 (Table 1) [1,2]. The most common form
among CTCLs is mycosis fungoides (MF), accounting
for around 55% of cases. Se´zary syndrome (SS) is much
rarer making up only approximately 5%. A recent
analysis by the Surveillance, Epidemiology and End
Results (SEER) program of the United States National
Cancer Institute (NCI) demonstrated an incidence rate
of MF of about 5.6 per million persons, which has
remained stable since 1995 after an increase in prior
years; this may be attributed to improvement in diag-
nostic accuracy [3].
The clinical presentation of MF is manifold with
early stages presenting with limited patches and plaques
suspicious only to the experienced physician and late
stages characterised by severe disease presenting with
tumours, ulceration, systemic involvement and death. A
number of clinical variants of MF have been described
of which folliculotropic MF, pagetoid reticulosis, and
granulomatous slack skin are separately mentioned in
the WHO-EORTC classification due to distinctive clin-
icopathological features and biological behaviour [1]. SS
is pathologically and clinically closely related to MF and
defined by the occurrence of erythroderma, lymphade-
nopathy and leukaemic involvement. Since the initial
description of MF ascribed to Jean-Louis Alibert in
1806 and of SS to Albert Se´zary in 1938, both from the
Hoˆpital Saint Louis in Paris, a number of therapeutic
options have been introduced ranging from topical ste-
roids to cytostatic chemotherapy and more recently also
molecular targeted approaches [4e7]. However, due to
the fact that in MF/SS the majority of available treat-
ments are rarely able to induce long-term remissions,
and according to the results of an early seminal study it
is still a paradigm that treatment of patients with MF/SS
is palliative and should follow a stepwise, stage-adapted
approach [8]. The rare exceptions to this are allogeneic
stem cell transplantation (alloSCT) in advanced disease
and the anecdotal patient with long-term remission after
skin-directed therapy (SDT) in early stages. These facts
together with the want of evidence from larger pro-
spective trials in an orphan disease has supported a need
for the development of consensus statements by various
national and international groups in which published
evidence is integrated with expert opinion to provide the
best available support for decision making in clinical
practice [6,7,9e12]. It was with this intention that in
2004 the Cutaneous Lymphoma Task Force of the
EORTC (EORTC-CLTF) embarked on an interna-
tional attempt to establish consensus recommendations
for the treatment of MF/SS with a special emphasis on
treatment availability and access in Europe that were
eventually published in 2006 [9]. As, in the meantime,
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our understanding of MF/SS pathophysiology and
prognostic parameters has improved, the original
tumour-node-metastasis classification (TNM) system of
staging has been updated and revised, and additional
treatment options have been developed; an update to
this collaborative effort has become timely and is pre-
sented in the following.
2. Development process of recommendations
The process to revise the published EORTC
consensus recommendations for the treatment of MF/SS
was initiated in October 2014. Original authors and
additional experts were contacted by e-mail, and com-
ments and suggestions for update to the original rec-
ommendations were collected. This was followed by an
interactive discussion at an EORTC Groups Annual
Meeting (EGAM) in March 2015 and a further final
collection of feedback by email. Thus current ‘best
practices’ from each national group were summarised
and discussed until a unanimous consensus on first and
second line therapies for each disease stage was estab-
lished. Since the order of options is largely based on
availability and institutional experience it was not
included in the consensus development process. As in
the previous document the recommendations are pre-
sented by disease stage and accompanied by ‘levels of
evidence’ to facilitate interpretation.
These recommendations were developed without
external funding. Individual authors’ potential conflicts
of interest are disclosed in a separate section at the end
of the article.
3. Levels of evidence
Revised Levels of Evidence have been published by The
Oxford Centre for Evidence-Based Medicine (OCEBM)
in 2011 and will be used in this article (Table 2) [13].
These revised levels of evidence have been simplified
when compared with the previous version; they were
designed with the specific aim of providing support for
clinicians for heuristic decision making thus ideally
suiting the purpose of this publication. However, the
initial sentence of the accompanying introductory
document should always be kept in mind when inter-
preting these recommendations: ‘No evidence ranking
system or decision tool can be used without a healthy
dose of judgment and thought.’ [14].
4. Staging
Staging of MF/SS is based on a tumourenodeemeta-
stasis (TNM) classification system originally devised in
1979 [15]. A revision and expansion that also includes
blood involvement (TNMB) has been published in 2007
and is used here for stratification of treatment recom-
mendations [16]. Recent studies have supported the
prognostic relevance of these newly refined stages
(Tables 3) [17e20]. Additionally, histological findings
Table 2
Detail from: Oxford Centre for Evidence-Based Medicine 2011 Levels
of Evidence [13].
Question: Does this intervention
help?
Levela
Systematic review of randomised
trials or n-of-1 trials
1
Randomized trial or observational
study with dramatic effect
2
Non-randomized controlled
cohort/follow-up studyb
3
Case series, caseecontrol studies,
or historically controlled
studiesb
4
Mechanism-based reasoning 5
a Level may be graded down on the basis of study quality, impre-
cision, indirectness (study PICO does not match questions PICO),
because of inconsistency between studies, or because the absolute effect
size is very small; Level may be graded up if there is a large or very
large effect size.
b As always, a systematic review is generally better than an individual
study.
Table 1
Classification of cutaneous T-cell lymphomas [1,2,180].
Cutaneous T-cell and NK-cell
lymphoma
ICD-O-3 (morphology)
Mycosis fungoides (MF) 9700/3
MF variants and subtypes:
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome (SS) 9701/3
Adult T-cell leukaemia/lymphoma
(ATLL)
9827/3
Primary cutaneous CD30-positive lymphoproliferative disorders:
Primary cutaneous anaplastic
large cell lymphoma
9718/3
Lymphomatoid papulosis 9718/1
Subcutaneous panniculitis-like T-
cell lymphoma
9708/3
Extranodal natural killer/T-cell
lymphoma, nasal type
9719/3
Hydroa vacciniforme-like
lymphoproliferative disease
9725/3
Primary cutaneous CD8þ
aggressive epidermotropic
cytotoxic T-cell lymphoma
(provisional)
9709/3
Primary cutaneous g/d T-cell
lymphoma
9726/3
Primary cutaneous CD4þ small/
medium T-cell
lymphoproliferative disorder
(provisional)
9709/3
Primary cutaneous acral CD8þ T-
cell lymphoma (provisional)
9709/3
Primary cutaneous peripheral T-
cell lymphoma, unspecified
9709/3
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that might be of prognostic importance but which are
not accounted for by the TNMB classification are the
infiltration of hair follicles (folliculotropism) and a
finding of >25% of large cells in the dermal infiltrate
(large cell transformation) [16].
5. Management options and treatment modalities
considered for inclusion in the consensus recommendations
In the following paragraphs a short description and
literature review of the various management options and
treatment modalities for MF/SS is provided. It should
be noted that the list is not comprehensive as it does not
include experimental treatments and modalities for
which only minor literature support exists. Special
emphasis is given to treatments that are available and
commonly used in Europe.
5.1. Expectant policy (watch and wait)
Patients with stage IA disease have a low risk of pro-
gression, which has been estimated to be 10% within 10
years, and a life expectancy that appears to be very
similar to that of an age and sex matched population
[20e22]. Thus the previously reached consensus is again
confirmed here to include ‘Expectant Policy’ as a legit-
imate management option for patients with MF stage
IA. However, this strategy must incorporate careful
monitoring and patient education as a few patients, who
currently cannot be identified with certainty in advance,
will eventually experience progression in their disease.
The influence of skin-directed therapy (SDT) on the
prevention of progression is not fully established.
Although reliable predictive biomarkers for progression
in MF are lacking there is evidence supporting that the
subdivision of IA and IB stages according to clinical
presentation into patch (T1/2a) and plaque (T1/2b)
disease might well be of prognostic significance
[16e18,20,23]. It is thus recommended to offer a ‘watch
and wait’ expectant policy only to informed T1a
patients.
5.2. Skin-directed therapy
5.2.1. Topical corticosteroids
Although only a single study exists on the use of topical
corticosteroids in MF, this therapy is widely used and is
commonly considered to be useful for palliation in the
treatment of individual lesions in early patch/plaque
disease [24]. In an uncontrolled study, Zackheim et al.
prospectively evaluated the twice-daily use of mainly
high-potency topical corticosteroids (clobetasol propio-
nate in 85% of patients) in 79 patients with stage IA/B
disease and observed an overall response rate of 94%
[25]. As no further published evidence exists, no other
advice can be given other than to assign preference to
high potency over less potent topical steroids. Toxicity is
Table 3b
Clinical stages (5-year disease free survival (DSS) according to [17]).
Stage T N M B 5-year
DSS (%)
IA 1 0 0 0.1 98
IB 2 0 0 0.1 89
IIA 1.2 1.2 0 0.1 89
IIB 3 0e2 0 0.1 56
IIIA 4 0e2 0 0 54
IIIB 4 0e2 0 1 48
IVA1 1e4 0e2 0 2 41
IVA2 1e4 3 0 0e2 23
IVB 1e4 0e3 1 0e2 18
Table 3a
TNMB staging for mycosis fungoides and Se´zary syndrome [16].
Skin
T1 Limited patches, papules, and/or plaques covering <10% of
the skin surface. May further stratify into T1a (patch only)
versus T1b (plaque  patch).
T2 Patches, papules, or plaques covering 10% of the skin sur-
face. May further stratify into T2a (patch only) versus T2b
(plaque  patch).
T3 One or more tumours (1-cm diameter)
T4 Confluence of erythema covering 80% body surface area
Node [181,182]
N0 No clinically abnormal peripheral lymph nodes; biopsy not
required
N1 Clinically abnormal peripheral lymph nodes; histopathology
Dutch grade 1 or NCI LN0e2
N1a Clone negative
N1b Clone positive
N2 Clinically abnormal peripheral lymph nodes; histopathology
Dutch grade 2 or NCI LN3
N2a Clone negative
N2b Clone positive
N3 Clinically abnormal peripheral lymph nodes; histopathology
Dutch grades 3e4 or NCI LN4; clone positive or negative
Nx Clinically abnormal peripheral lymph nodes; no histologic
confirmation
Visceral
M0 No visceral organ involvement
M1 Visceral involvement (must have pathology confirmation and
organ involved should be specified)
Blood
B0 Absence of significant blood involvement: 5% of peripheral
blood lymphocytes are atypical (Se´zary) cells
B0a Clone negative
B0b Clone positive
B1 Low blood tumour burden: >5% of peripheral blood lym-
phocytes are atypical (Se´zary) cells but does not meet the
criteria of B2
B1a Clone negative
B1b Clone positive
B2 High blood tumour burden: 1000/mL Se´zary cells with posi-
tive clone
SS is staged as T4 N2/3/x M0 B2.
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negligible if the precautions usually associated with the
use of these topical agents in chronic skin conditions are
followed.
5.2.2. Topical mechlorethamine (HN2)
Mechlorethamine is an alkylating agent that received its
initial approval in the United States of America (USA)
for the topical treatment of MF in 1949. It is only
recently that based on the results of a pivotal phase II
study a commercial 0.02% gel preparation was approved
by the US Food and Drug Administration (FDA) for
the treatment of stage IA and IB mycosis fungoides-type
cutaneous T-cell lymphoma in patients who have
received prior skin-directed therapy [26e28]. Two-hun-
dred sixty patients with MF stage IAeIIA who had not
used topical mechlorethamine within 2 years and were
naı¨ve to treatment with topical carmustine were
included in the pivotal study and randomly allocated to
the commercial gel preparation or a 0.02% compounded
mechlorethamine ointment. The 0.02% gel proved non-
inferior to the ointment (response rates 58.5% versus
47.7%, respectively) with a significantly shorter time-to-
response. No drug-related serious adverse events
occurred within a duration of treatment of up to 12
months. However, more than 50% of patients in both
groups experienced skin-related adverse events, most
commonly irritant contact dermatitis leading to with-
drawal in 20.3% and 17.3% of patients (gel versus
ointment, respectively) [27]. The gel should be applied
once daily to all affected areas of the skin. The product
has recently been granted marketing authorization in
Europe as an orphan medicinal product for the treat-
ment of ‘mycosis fungoides-type cutaneous T-cell lym-
phoma’. According to published evidence and upon its
availability it is recommended for first line treatment of
early stage disease (stages IAeIIA).
A number of large, uncontrolled studies on the use of
various compounded formulations of mechlorethamine
have been reported, mostly from groups in the USA but
including also a Danish cohort that show response rates
of up to 83% depending on disease stage and no sig-
nificant evidence for long-term toxicity or an increased
rate of secondary cutaneous malignancies [9,29e31].
5.2.3. Topical bexarotene
Bexarotene is a retinoid that selectively binds and acti-
vates retinoid X receptors (‘rexinoid’). It is available for
systemic therapy (see below) and in a 1% gel formula-
tion for topical application. The gel is approved by the
FDA for topical treatment of cutaneous lesions in pa-
tients with CTCL (Stage IA and IB) who have refractory
or persistent disease after other therapies or who have
not tolerated other therapies. The overall response rates
reported from two prospective trials are between 44%
and 63% depending on study end-point definition with a
time to response between 28 and 504 days [32,33].
Toxicity is mild and mainly restricted to skin irritation.
Like other retinoids, bexarotene is teratogenic and is
thus contraindicated in pregnancy and requires special
precautions in women of childbearing potential and
male partners thereof. The product is not approved in
Europe and no recommendation as to its use will thus be
included in the current consensus.
5.2.4. Ultraviolet (UV) phototherapy
8-Methoxypsoralen plus ultraviolet A (UVA)
(320e400 nm, PUVA) and ultraviolet B (UVB), either
broadband (290e320 nm, bbUVB) or narrow band
(311e312 nm, nbUVB), have a longstanding history in
the treatment of MF with a large number of patients
reported in retrospective and prospective cohorts. Other
emerging variants of UV-phototherapy include excimer
sources (308 nm) and UVA1 (340e400 nm) [34]. Only
PUVA and UVB will be included into the options rec-
ommended here as only these are widely available,
accessible to many patients and supported by ample
evidence. Recent reviews on the topic have been pub-
lished including a comprehensive consensus statement
from the United States Cutaneous Lymphoma Con-
sortium [34e36], which provide an excellent overview on
the pertinent data.
In clinical practice today, broadband ultraviolet B
(bbUVB) has become inaccessible to most patients as
sources emitting bbUVB have mostly been replaced by
narrow band ultraviolet B (nbUVB) lamps, which have
been developed by van Weelden as a less erythemogenic
and more effective treatment for psoriasis [35,37].
Similarly, there seems to be no disadvantage in the
treatment of MF, as the efficacy of nbUVB to induce
remissions in early MF, demonstrated initially in 1999,
was subsequently confirmed in a number of studies
without any evidence of inferiority compared with
bbUVB [38,39]. This together with other practical ad-
vantages make nbUVB a primary option for the treat-
ment of early MF, particularly stages T1a and T2a,
which are characterised by patches only. For plaque
disease (T1b, T2b) and for patients with dark skin
PUVA is still recommended. This is not only due to
mechanistic reasoning (UVA is able to penetrate deeper
into the dermis than UVB and thus should theoretically
be more effective for the treatment of thick lesions) but
also to the large body of evidence that has accumulated
since the first report of the successful use of PUVA for
MF in 1976 and to the lack of prospective studies
comparing nbUVB to PUVA [34,40].
Technically, phototherapy in MF is prescribed and
applied in analogy to what is established and routinely
used for the treatment of psoriasis. PUVA is usually
done with 8-methoxypsoralen supplied orally. Although
bath PUVA with 8-methoxypsoralen has been shown in
a small retrospective analysis to be effective, its use is
not generally recommended because with bath PUVA
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the head is usually not exposed to the photosensitiser
and might be a site of early relapse [41,42]. Although
evidence is anecdotic, cream PUVA, where 8-
methoxypsoralen is only applied to the disease site,
may be used for unilesional disease and pagetoid retic-
ulosis [43].
Upon insufficient response or immediate relapse
phototherapy can be combined with systemic therapies,
most commonly retinoids or interferon a (IFN-a) (see
below). Another widely used practice to prevent relapses
or to maintain responses is to continue therapy for
prolonged periods after complete or almost complete
responses have been achieved (maintenance therapy, see
below).
An important issue relating to phototherapy of MF is
long-term toxicity, particularly as the major target
population, namely patients with early stages might
have a normal or almost normal life expectancy. For
patients with psoriasis an increased risk of squamous
cell carcinoma associated with PUVA has been well
defined from a large prospective cohort study whereas
for UVB less thoroughly performed studies could not
show an increased cancer risk [44,45]. For patients with
MF, similar studies have not been done, and their risk of
skin cancer associated with phototherapy is unknown.
5.2.5. Total skin electron beam therapy
In total skin electron beam (TSEB) therapy, electrons,
generated in a linear accelerator, are attenuated to
penetrate the skin to a limited depth. Thus toxicity to
internal organs including the bone marrow is largely
avoided. The technique has a long history in the treat-
ment of cutaneous lymphomas and already in 1961 a
nine-year follow up of 200 patients was reported [46].
Since then, not only radiation technology has advanced
but also clinical experience from large centres has helped
to refine the method to provide a sufficiently distributed
dose to the target volume to reliably induce remission
with acceptable toxicity. Based on evidence from retro-
spective studies, which have been extensively reviewed, a
standard treatment course consisting of a total dose of
30e36 Gy applied over a period of 8e10 weeks is able to
induce high remission rates, particularly in T2 and T3
disease. In selected patients with relapse after good
initial response treatment has been successfully repeated
without significant additional toxicity. TSEB can be
combined with nodal and localised skin irradiation
[47,48].
Consensus guidelines on the use of TSEB in MF have
been published [49e52]. However, toxicity of TSEB is
dose-related and the recommended dose as mentioned
above is based on experience and theoretic reasoning
rather than on comparative trials. More recently, low-
dose regimens (in the range of 10e12 Gy) have been
investigated for their clinical efficacy. No direct com-
parisons with standard dose TSEB exist and it is
currently unknown whether low-dose regimens with
their associated lower toxicity, shorter treatment times
(2e3 weeks) and the additional advantage of allowing
multiple re-treatments, will be equally effective in
inducing remissions [53e57].
5.2.6. Localised radiotherapy
Localised, superficial radiotherapy provides effective
palliative treatment for individual lesions and may even
induce long-term remission in unilesional disease. Pho-
tons as well as electron beam have been used and doses
have ranged from 0.7 to 35 Gy and may be fractionated
[54,58e60]. In one study brachytherapy was successfully
used for facial lesions [61]. Localised radiotherapy can
be either used alone (particularly in unilesional MF and
pagetoid reticulosis) or in combination with systemic or
other skin directed therapies. For unilesional MF and
pagetoid reticulosis a dose of 20e24 Gy is advised [57].
In patients with more advanced disease isolated plaques
or tumours can be treated for effective palliation with
low-doses (2  4 Gy) [62].
5.3. Systemic therapies
5.3.1. Retinoids (incl. bexarotene)
Retinoids are derivatives of vitamin A. All-trans retinoic
acid, isotretinoin, etretinate, acitretin and e more
recently e bexarotene and alitretinoin have been used
for the treatment of cutaneous T-cell lymphomas alone
or in combination since the early 1980s [63e65]. Among
these bexarotene stands out through its specific binding
to the retinoid-X-receptor (thus termed a ‘rexinoid’); it is
the only member of the group that was specifically
developed and has received approval for the treatment
of CTCL [66e69]. According to its label, bexarotene is
indicated for the treatment of cutaneous manifestations
of advanced stage CTCL in patients who are refractory
to at least one prior systemic therapy with a reported
overall response rate of 45% [70]. In clinical practice,
bexarotene has been used as primary systemic therapy
and has shown efficacy also in extracutaneous involve-
ment [68,71,72]. The other most commonly used
although not approved and less thoroughly studied
retinoids are acitretin (which has replaced its prodrug
etretinate in the 1990s) and isotretinoin [64]. Due to
heterogeneity of the published evidence and since no
direct comparisons exist no conclusion as to superiority
in clinical efficacy of one substance over the other can be
made.
Retinoids are generally well tolerated and share a
common adverse effect profile with variable individual
symptoms depending on the substance used. Most
commonly observed are drying of the skin and mucous
membranes, elevated blood lipids, and in the case of
bexarotene central hypothyroidism requiring thyroid
hormone substitution in most patients [73]. All retinoids
are teratogenic.
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With retinoids as monotherapy moderate response
rates can be achieved in MF/SS, the substances thus are
commonly used in combination (see below) or in
maintenance (see below) since they appear safe with
long-term use.
5.3.2. Interferon (IFN)-a
Three types of recombinant interferons (IFN-a, IFN-b,
IFN-g) are currently available for therapeutic use with
IFN-a existing also in a pegylated form. Therapeutic
activity of IFN-a in CTCL was initially reported by
Bunn et al., in 1984 [74]. The same author some years
later summarised the then pertinent evidence and
concluded that all of the recombinant IFNs are active
for the treatment of MF and SS [75]. However, only
recombinant IFN-a has been studied in more detail, has
received approval for the treatment of CTCL and re-
mains the most widely used IFN in the treatment of
MF/SS [76]. Various treatment and dose escalation
schedules have been used with individual doses ranging
from 3 million units (MU) to 18 MU applied subcuta-
neously either three times per week or daily. A
commonly used regimen is to start with 3 MU three
times weekly with dose escalation upon insufficient
response and tapering for maintenance.Side-effects are
dose dependent and include flu-like symptoms, elevated
transaminases, leukopenia, thrombocytopaenia, and e
probably under-recognized mental depression, cardiac
arrhythmias, and thyroid dysfunction [76,77]. Similar to
the literature on the older retinoids (with the exception
of bexarotene, see above), published evidence on the
clinical efficacy of IFN-a suffers from heterogeneity in
treatment schedule, patient selection, and methodology.
Thus, reported overall response rates range from 0 to
80% without a clear correlation between dose and
response [76].
5.3.3. IFN-a combined with retinoids
Reports on the combined use of IFN-a and retinoids
appeared beginning from the late 1980s [78e81]. Etre-
tinate or isotretinoin have been used in these small
heterogenous studies, which showed that the combina-
tion is tolerable without unexpected toxicity and is able
to induce and maintain clinical responses. In the pro-
spective randomised study by Stadler et al. acitretin was
used in combination with IFN-a and compared with the
IFN-a e PUVA combination in 82 patients with early
stage MF [82]. Although overall response rates did not
differ between treatment groups (90.5% versus 90%,
respectively) the rate of CR was higher with IFN-a/
PUVA (70%) compared with the acitretin combination
(38%). The study clearly shows that IFN-a plus PUVA
is superior to IFN-a plus acitretin in terms of time to
remission and CR rate. However, its results should not
be interpreted as an argument to dismiss the latter
combination since its efficacy, shown in earlier less
stringent trials, was confirmed and it fulfils a need for
combination therapy in patients insufficiently respond-
ing to monotherapy when access to PUVA is limited.
More recently the combination of tretinoin (all-trans
retinoic acid) with IFN-a has been compared with IFN-
a combined with low-dose methotrexate in an open
prospective non-randomised trial [83]. Reportedly, both
regimens were of similar efficacy and toxicity. In another
small trial IFN-a was added to bexarotene upon
incomplete remission after 8 weeks with no apparent
benefit of the combination [84]. Taken together, the
accumulated evidence confirms the clinical applicability
of IFN-a e retinoid combinations in MF. At the same
time it fails to demonstrate the superiority of any reti-
noid over the other and of the various combination
regimens over monotherapy. Thus a combination of
IFN-a and retinoids is recommended when mono-
therapy with either substance has failed and when the
IFN-a e PUVA combination is contraindicated or
unavailable.
5.3.4. IFN-a or retinoids combined with SDT
The combination of PUVA with systemic retinoids was
initially developed to improve efficacy and reduce po-
tential side-effects of photochemotherapy in the treat-
ment of psoriasis [85]. Subsequently, the concept was
carried over to CTCL and investigated in a small series
of uncontrolled studies and case collections [86e88].
Etretinate and acitretin were used in these studies from
which no conclusion as to superiority of the combina-
tion over phototherapy alone can be made. With the
systematic development and regulatory approval of
bexarotene for the treatment of CTCL interest in the
combination of this substance with phototherapy led to
the publication of a number of reports [89e93].
Outstanding among these studies is a randomised phase
III trial conducted by the EORTC Cutaneous
Lymphoma Task Force where bexarotene combined
with PUVA was compared to PUVA alone in early
stage (IBeIIA) MF. The study was closed prematurely
due to low accrual and thus did not reach its primary
end-point (overall response rate). However, while con-
firming the safety of the combination its results indicate
no significant difference in response rate and response
duration between treatments [91].
The first small study about the use of combining
IFN-a and PUVA for the treatment of CTCL appeared
in 1990 and described complete remission in 12 out of a
total of 15 patients [94]. A number of further small
studies and case series followed [95e100] using various
IFN-a dose schedules and PUVA regimens. Taken
together these reports demonstrate that no increase in
toxicity occurs with the combination but leave open the
question whether it is more effective compared to
monotherapy. Safety and efficacy IFN-a plus PUVA
were confirmed by the above mentioned prospective trial
[82] leaving, however, the issue of superiority compared
to either monotherapy unresolved.
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Other SDT that can be combined with systemic
treatments are topical corticosteroids, nbUVB and
localised radiotherapy (see above). Although not sys-
tematically studied these options are used based on
institutional and personal experience and might prove
useful on an individual basis.
In summary, current evidence does not support the use
of combinations of SDT with systemic therapies as first
line option in early stages of MF. However, when sys-
temic therapy is indicated in more advanced stages add-
ing on of an effective SDTmight shorten time to response
and alleviate symptoms more quickly and effectively.
5.3.5. Chemotherapy
Conventional single agent and combination chemo-
therapy have been used for the treatment of non-
Hodgkin lymphoma since the 1970s with the (C)yclo-
phosphamide-(H)ydroxydaunorubicin-(O)ncovin-(P)
rednosone or (P)rednisolone [CHOP] regimen evolving
as a long-standing standard option for aggressive dis-
ease. At the same time this and a number of other
combinations and single agents have been tried in
CTCL with variable, but generally short-lived success.
A comprehensive review on these early experiences is
published elsewhere [101]. Already in 1989, the results
of a seminal prospective randomised trial comparing
early aggressive with stage-adapted therapy restricted
(poly-) chemotherapy to patients with advanced dis-
ease, a restriction still applying today [8]. In the
meantime novel chemotherapeutic agents with activity
in MF and SS have been developed. Among these
promising results with acceptable toxicity have been
obtained with pegylated liposomal doxorubicin
[102e107] and gemcitabine [108e112]. Treatment reg-
imens in these studies largely followed established
dosage recommendations as described for their
approved indications. In an EORTC-sponsored pro-
spective multicentre trial Dummer et al. could
demonstrate an acceptable safety profile and an overall
response rate of 40.8% in 49 patients with pre-treated
(2 previous therapies) advanced stage (IIB, IVA, or
IVB) MF using pegylated liposomal doxorubicin at
20 mg/m2 biweekly. Median duration of response was 6
months, similar to what has been reported for other
chemotherapy regimens in this high risk population
[106]. Gemcitabine was also investigated in combina-
tion with bexarotene in a phase II protocol resulting in
poor response rates and increased toxicity compared to
the single agents leading to the conclusion that this
combination should be avoided [113]. A number of
other cytotoxic agents have been tried in CTCL
including the purine analogues (deoxycoformycin, 2-
chlorodeoxyadenosine, fludarabine), bendamustine
and others [114e119]. However, limited published ev-
idence precludes inclusion of these substances in the
present recommendations.
Two other chemotherapeutic agents are included in
these recommendations and thus will be mentioned
briefly:
Chlorambucil is an alkylating agent that was devel-
oped in the 1950s for the treatment of chronic lym-
phocytic leukaemia and non-Hodgkin lymphomas [120].
It can be administered by mouth. In combination with
low dose prednisone it was introduced for the treatment
of SS in the 1970s by Winkelmann [121,122]. The orig-
inal regimen consists of continuous treatment with
2e6 mg/day of chlorambucil and prednisone at an initial
dose of 20 mg/day to be tapered to 0e10 mg/day.
Although more recently a variant with intermittent
dosing was described in a small patient series to be as
effective as the original regimen the original prescription
is still recommended [123]. However, since in addition to
myelosuppression prolonged exposure to chlorambucil
carries a leukemogenic risk long-term continuous use
should be avoided [124].
Methotrexate was developed as a cytotoxic antifolate
in the wake of the 1950s breakthrough of anticancer
chemotherapy for the treatment of childhood leukae-
mias [125]. Soon afterwards its usefulness for treatment
of psoriasis and rheumatoid arthritis was demonstrated
and low-dose once-weekly methotrexate has become a
well-tolerated, standard treatment for non-oncological
conditions [126]. There are only few studies on the use
methotrexate in various dosing for the treatment of MF/
SS that have been reviewed earlier [9]. Since then addi-
tional experience on the safe combination of metho-
trexate with bexarotene and IFN-a, respectively, have
been published [83,127]. No conclusion, however, as to
the superiority of these combinations over monotherapy
is possible and no recommendation as to the optimal use
of these regimens can be made. In the context of this
consensus the recommended dose of methotrexate is
5e25 mg once weekly.
5.3.6. Targeted immunotherapy
Since the introduction of monoclonal antibodies into
cancer therapy in the 1990s a number of recombinant
immunoglobulins and other protein constructs have also
been developed for and tried in non-Hodgkin lym-
phomas, with rituximab as a most remarkable example
of success in B-cell lymphomas [128]. Some agents have
also demonstrated activity in CTCL and it is to be ex-
pected that in the near future new antibodies and
antibody-constructs will enter the clinics [129].
Denileukin diftitox was developed for the treatment of
CTCL and became the first fusion toxin to be approved.
It is a recombinant protein consisting of interleukin
(IL)-2 linked to the catalytic domain of diphtheria toxin
genetically engineered with the intention to target cells
expressing the IL-2 receptor [130]. Its activity in the
treatment of CTCL has been demonstrated in two phase
III trials with overall response rates of 30% and 44% and
an acceptable safety profile although grade 3 and 4
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capillary leak syndrome was observed in 4% of patients
[131,132]. Since denileukin diftitox is currently unavai-
lable and did not obtain marketing authorisation in
Europe its use is not included in these consensus
recommendations.
Alemtuzumab is a humanised recombinant IgG1
monoclonal antibody against the CD52 cell surface
glycoprotein, which is expressed on normal and malig-
nant B and T lymphocytes but not on haematopoietic
progenitors. Alemtuzumab was initially developed and
approved for the treatment of lymphoid malignancies.
More recently its immunosuppressive effects have been
utilised to successfully treat multiple sclerosis [133,134].
Although alemtuzumab is currently commercialised
only for multiple sclerosis it is still available for the
treatment of lymphoid neoplasms through a special ac-
cess programme. Overall response rates of more than
50% have been obtained In MF/SS using the standard
dose of 30 mg intravenous (i.v.), three times weekly. At
this dosage immunosuppression and opportunistic in-
fections are the most common, sometimes severe adverse
events [135e137]. From these studies and a recent long-
term observation it appears that alemtuzumab is effec-
tive primarily in patients with erythroderma (T4) and
blood involvement (B  1) and may be able to induce
long-term remissions in selected patients [138]. With the
intention to reduce toxicity while maintaining efficacy
low dose regimens have been introduced [139e141].
Doses up to 15 mg s.c. every other day were used and in
small patient series response rates similar to those re-
ported from earlier studies were observed without rele-
vant infectious complications when single doses did not
exceed 10 mg.
Brentuximab vedotin is an antibody-drug conjugate
consisting of an anti-CD30 IgG1 antibody attached to
monomethyl auristatin E, a microtubule-disrupting
agent, through a protease-cleavable linker [142]. Upon
internalisation into CD30 expressing cells the linker is
cleaved and monomethyl auristatin E released into the
cell to induce cell cycle arrest. The drug is currently
approved in Europe and the USA for the treatment of
adult patients with relapsed or refractory CD30þ
Hodgkin lymphoma (HL), patients with CD30þ HL at
increased risk of relapse or progression following
autologous stem cell transplantation, and adult patients
with relapsed or refractory systemic anaplastic large cell
lymphoma (sALCL). The safety and efficacy of bren-
tuximab vedotin in CTCL has been investigated in two
phases II and one very recently reported phase III trials
[143e145]. In one of these studies 32 patients with MF/
SS and any level of CD30 expression were included. An
overall response rate of 70% observed in patients with a
wide range of CD30 expression and a lower likelihood
of response if CD30 was expressed in less than 5% of
cells as assessed by immunohistochemistry [144]. In the
other study 48 patients with CD30þ CTCL (incl. lym-
phomatoid papulosis, primary cutaneous anaplastic
large cell lymphoma, and CD30þMF/SS) were included
with an overall response rate of 73% in the total study
population and of 54% in patients with MF/SS (nZ 28).
The main toxicities consisted of peripheral neuropathy,
that can be dose-limiting, severe, and long-lasting,
neutropenia, that can be severe; fatigue, nausea and al-
opecia. First results of a randomised, controlled phase
III trial comparing brentuximab vedotin to physician’s
choice of methotrexate or bexarotene in pre-treated
CD30þ CTCL have been recently reported [145]. In the
intention-to-treat population of 128 patients highly
significant improvements in the rate of overall responses
lasting 4 months (56% versus 13%) and progression
free survival (16.7 versus 3.5 months) were observed
with brentuximab vedotin. Reported observed adverse
events appear consistent with the reported safety profile
of brentuximab vedotin. As at the date of writing
brentuximab vedotin is not approved for the treatment
of patients with MF/SS its use is not recommended in
this consensus. However, based on the above mentioned
level 2 evidence and since the drug is widely available in
Europe it may be used on an individual basis upon
physician’s decision in advanced CD30þ cases.
Mogamulizumab is a humanized monoclonal anti-
body targeting the CC chemokine receptor 4 (CCR4)
expressed on tumour cells of adult T-cell leukaemia-
lymphoma (ATLL) and other T-cell lymphomas. The
antibody is modified in the composition of its carbo-
hydrates (‘glyco-engineered’) to enhance its antibody-
dependent cell-mediated cytotoxic (ADCC) activity
[146]. Currently the drug is approved in Japan for
relapsed or refractory CCR4þ peripheral T-cell lym-
phoma and CTCL. In 3 early phase studies a total
population of 48 patients with relapsed CCR4þ CTCL,
pre-treated MF and SS were treated with mogamulizu-
mab with overall response rates between 38% and 29%
mainly in leukaemic CTCL variants. Reported side-ef-
fects were mostly low grade and included chills, fever,
rash, nausea, headache and infusion-related reactions
[147e149]. Thus, although promising, the published
evidence on the efficacy of mogamulizumab in the
treatment of MF/SS is sparse and the results of an
ongoing randomised phase III trial against vorinostat in
pre-treated CTCL (NCT01728805) have to be awaited
before further recommendations can be made.
5.3.7. Extracorporeal photochemotherapy
Extracorporeal photochemotherapy (ECP; which has
also been variously called photopheresis, extracorporeal
photopheresis, or extracorporeal photoimmunotherapy)
is a form of phototherapy where blood is exposed
extracorporeally to the photoactivated drug 8-
methoxypsoralen (8-MOP). The use of ECP was first
reported in 1987 by Edelson et al. in CTCL for which it
is approved in Europe and the US [150]. Other in-
dications where ECP is used include systemic sclerosis,
graft-versus-host disease, solid organ transplant
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rejection, and Crohn’s disease [151]. ECP has an excel-
lent safety profile with almost absent adverse events and
details on the recommended prescription, schedule, and
other practical issues have been recently published
elsewhere [152]. Since the original publication by Edel-
son et al. who reported a response rate of 73% (with
most of the patients having T4 disease) a number of case
series and retrospective studies confirming the efficacy of
photopheresis particularly in patients with eryth-
rodermic MF and SS have been published with response
rates around 60% [153]. Remarkably in most of these
reports ECP was used in combination with other agents
and modalities, including retinoids, interferons, PUVA,
and others, demonstrating on the one hand that ECP
can be safely combined with many other agents avail-
able for the treatment of MF/SS, and leaving open, on
the other hand, the question of superiority of any
combination over the other and over monotherapy.
5.3.8. Haematopoietic stem cell transplantation
The first transfer of haematopoietic stem cells from
allogeneic bone marrow to terminally ill patients was
published in 1957 by E. Donnall Thomas who was
awarded the Nobel Prize for his achievements in 1990
[154]. In the meantime the technique has been refined
through advances in immunological understanding and
with the development of efficient protocols for stem cell
collection from peripheral and umbilical cord blood,
conditioning and support of engraftment after trans-
plantation. Major indications today still include hae-
matological malignancies but have been extended to
hereditary bone marrow disease such as thalassaemia
and sickle cell anaemia. The first report on autologous
stem cell transplantation (ASCT) after total body irra-
diation in MF appeared in 1991 and described complete
remission in five out of six patients with early relapse in
three of the responders [155]. Other small case series
confirmed that although aggressive treatment with
ASCT rescue is feasible and able to induce remissions
almost all patients will eventually relapse [156]. Conse-
quently this approach has been abandoned in MF/SS
and is not recommended in this consensus. With allo-
geneic stem cell transplantation (alloSCT) on the other
hand durable remissions have been achieved in CTCL
and (with the exception of localised radiotherapy for
unilesional MF) remains the only treatment option in
MF/SS with curative intention. The published evidence
from retrospective studies and case series on alloSCT in
CTCL comprises nine studies on a total of approxi-
mately 250 patients [157e165]. A comprehensive sum-
mary and review has been published recently [156].
Both, myeloablative and reduced-intensity conditioning
have been used with similar efficacy and lower compli-
cation rates including reduced non-relapse mortality
(NRM) and lower rates of chronic graft versus host
disease (GvHD) in the latter. Graft versus lymphoma
(GvL) effect appears to be important for induction and
maintenance of remission and donor lymphocyte in-
fusions and tapering of immunosuppression have been
demonstrated to induce secondary remission. In the
study with the longest reported observation time overall
survival was 46% and 44% at 5 and 7 years after
transplant, respectively, with 22% NRM [165]. In sum-
mary, alloSCT e particularly using reduced-intensity
conditioning e is able to induce long-term remissions
in a substantial percentage of patients with MF/SS
although at the price of a high rate of treatment related
morbidity and mortality. Consequently, patient selec-
tion is difficult, requires careful counseling and should
focus mainly on younger, well performing patients
suffering from advanced stages of the disease, with a low
tumour burden at the time of transplantation and at the
same time a high predictable risk of progression and
poor prognosis.
5.3.9. Histone deacetylase inhibitors
Histone deacetylases (HDAC) are a class of ubiqui-
tously expressed enzymes, that catalyse the removal of
acetyl groups from histones and by this are key regula-
tors of epigenetic regulation of transcription. Specific
pharmacological inhibitors of HDAC have been devel-
oped and investigated in preclinical and clinical studies
for their potential as novel antitumour agents that work
through modification of the epigenetic aberrations
associated with cancer [166]. Based on the results of
pivotal trials three substances, vorinostat, romidepsin,
and belinostat are currently approved by the FDA for
‘treatment of cutaneous manifestations in patients with
cutaneous T-cell lymphoma (CTCL) who have pro-
gressive, persistent or recurrent disease on or following
two systemic therapies’ (vorinostat);‘treatment of cuta-
neous T-cell lymphoma (CTCL) in patients who have
received at least one prior systemic therapy’ and ‘treat-
ment of peripheral T-cell lymphoma (PTCL) in patients
who have received at least one prior therapy’ (romi-
depsin); and for ‘treatment of patients with relapsed or
refractory peripheral T-cell lymphoma’ (belinostat)
[167e172]. Efficacy and toxicity of these substances are
similar with a reported overall response rate of about
30% and class-as well as substance specific toxicities,
most notably gastrointestinal side-effects, thrombocy-
topaenia, QTc prolongation, and deep vein thrombosis
with vorinostat. New substances are in development and
the clinical efficacy and toxicity of HDAC inhibitors in
CTCL have been recently reviewed elsewhere [173].
Since currently none of these drugs has obtained
approval in Europe HDAC inhibitors will not consid-
ered in these consensus recommendations.
5.4. Maintenance
MF/SS are chronic conditions that are generally
considered incurable with the main aim of treatment in
achieving effective palliation, i.e. remission of symptoms
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with improvement or at least maintenance of quality of
life. The exceptions mentioned above are alloSCT and
radiotherapy of unilocalised disease where long-term
remissions have been observed and treatment is pre-
scribed with the intention to cure. All other treatment
strategies have a variable potential to achieve remissions
in appropriately selected patients. However, almost all
patients will eventually experience relapse or progres-
sion either during ongoing treatment or after its cessa-
tion [174]. In this context maintenance therapy can be
defined as a continuous exposure to a skin directed or
systemic therapy once remission has been achieved with
the aim to maintain response and prevent relapse and
progression. As a consequence to qualify for the use as
maintenance modalities treatments must be selected to
be effective, palliative, available, and easy to apply, i.e.
have an excellent safety profile and not or only mini-
mally interfering with quality of life. These criteria a
largely fulfilled by a number of treatment options
mentioned in this report (Table 9) and some of them are
widely used in clinical practice, although without sup-
portive evidence, e.g. PUVA [35,175]. Practically,
maintenance can be performed with tapering of the
remission-inducing treatment as is commonly done with
phototherapy, retinoids, IFN-a, ECP, and others or
with the introduction of a maintaining treatment after
remission has been achieved with a method that has
dose-limiting toxicity, e.g. TSEB and systemic chemo-
therapy. As no guiding evidence exists on the indication
and selection of maintenance in MF/SS decisions should
be considered mainly in patients IB (T2b) with high
risk of relapse and/or progression after consideration of
the prerequisites described above and careful
counseling.
6. Treatment recommendations by disease stage
Stagewise consensus recommendations for the selection
of a treatment are laid out in Tables 4e8, subdivided
Table 4a
Recommendations for first-line treatment of MF stages IA, IB, and
IIA.
Expectant policy (mainly T1a) Level 4
SDT Topical corticosteroids
(mainly T1a and T2a)
Level 3
UVBa (mainly T1a and T2a) Level 2
PUVAb Level 2
Localised RT (for localised
MF including pagetoid reticulosis)
Level 4
Mechlorethaminec Level 2
a See text for details on recommended light sources.
b See text for details on recommendations as to the use of oral,
topical, and bath PUVA.
c Most of the evidence was obtained using compounded formula-
tions; a commercial product is available in the US with marketing
authorisation pending in Europe (see text for further details).
Table 4b
Recommendations for second-line treatment of MF stages IA, IB, and
IIA.
Systemic therapiesa
Retinoidsb Level 2
IFN-a Level 2
TSEB (mainly T2b) Level 2
Low-dose MTX Level 4
a The following agents are most commonly combined with PUVA,
combinations with other modalities and with each other are also
widely used.
b Including RAR and RXR agonists.
Table 5a
Recommendations for first-line treatment of MF stage IIB.
Systemic therapiesa
Retinoidsb Level 2
IFN-a Level 2
TSEB Level 2
Monochemotherapy
(gemcitabine, pegylated
liposomal doxorubicine)
Level 4
Low dose MTX Level 4
Localised RTc Level 4
a The following agents are most commonly combined with PUVA,
combinations with other modalities and with each other are also
widely used.
b Including RAR and RXR agonists.
c Used as add-on treatment in combination with systemic and other
skin directed therapies.
Table 5b
Recommendations for second-line treatment of MF stage IIB.
Polychemotherapya level 3
Allogeneic stem cell transplantationb level 3
a CHOP is the most widely used regimen with a number of variants
and other combinations available.
b Should be restricted to exceptional patients, see text for details.
Table 6a
Recommendations for first-line treatment of MF stage IIIA and B.
Systemic therapiesa
Retinoidsb Level 2
IFN-a Level 2
ECPc Level 3
Low dose MTX Level 4
TSEB Level 2
a The following agents are most commonly combined with PUVA,
combinations with other modalities and with each other are also
widely used.
b Including RAR and RXR agonists.
c ECP can be used alone or in combination with skin directed and
other systemic therapies.
Table 6b
Recommendations for second-line treatment of MF stage IIIA and B.
Monochemotherapy (gemcitabine,
pegylated liposomal doxorubicine)
Level 3
Allogeneic stem cell transplantationa Level 3
a Should be restricted to exceptional patients, see text for details.
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into first- and second-line options, where second line
options should be reserved for patients who are re-
fractory or have contraindications to first line therapy.
In this context a patient is considered refractory to a
specific treatment if he shows no or only minimal
response and upon progression under treatment. In case
of relapse after a successful course of a first line
treatment patients should not be considered refractory
and therapy can be reinitiated in most cases. As in the
previous version of this report no division into first- and
second-line options is made for stage IV disease as ac-
cording to the opinion of the authors pertinent evidence
as well as personal experience is insufficient to justify
such a separation. The order of recommendations is
based on the consensus opinion of the authors whenever
possible. The individual choice of the appropriate ther-
apy can differ and will depend on clinical presentation
and treatment availability. Furthermore, in addition to
clinical stage histological evidence of folliculotropism
and large cell transformation can be associated with
poorer outcome and more aggressive treatment might be
considered [176e179].
7. Summary and conclusion
Following up on the initial report from the EORTC-
CLTF on treatment of MF/SS we provide here a timely
update based as before on a broad consensus among a
representative group of experts from multiple European
countries.
Although additional evidence has accumulated
within the last 10 years, evidence levels supporting in-
dividual therapies are still low (with a few exceptions)
and progress is gradual. The main changes regard
treatment schedules and dosages (e.g. TSEB and alem-
tuzumab), more detailed specifications as to the prefer-
ence of specific chemotherapeutic agents, and the
inclusion of maintenance options and alloSCT and into
the recommendations.
In general the principles on treatment selection in
MF/SS as stated in the summary of the preceding
version of this report still apply, namely that patients
with early stage disease should primarily be treated with
SDT and should they relapse to the skin receive further
courses of the same or another SDT. Systemic therapy
should be mainly considered for patients with advanced
stages and for refractory cutaneous disease. Ideally,
patients with advance-stage disease should have the
option to enter multicentre clinical trials. Finally, as
treatment of MF/SS is still palliative in almost all cases
maintenance of quality of life should be at the centre of
therapeutic strategies and be considered alongside
response rates in clinical research.
Disclaimer
These recommendations reflect the best data available at
the time the article was prepared. Caution should be
exercised in interpreting the data; the results of future
studies may require alteration of the conclusions or
recommendations in this report. It may be necessary or
even desirable to depart from these recommendations in
special circumstances. Just as adherence to guidelines
Table 7
Recommendations for treatment of MF stages IVA and IVB.a
Chemotherapy (gemcitabine, pegylated
liposomal doxorubicine, CHOP and CHOP-like
polychemotherapy)b
Level 3
Radiotherapy (TSEB and localised)c Level 4
Alemtuzumab (mainly in B2) Level 4
Allogeneic stem cell transplantation Level 3
a For treatment of MF stage IVA1 recommendations for SS (Table
8a and b) might apply.
b Monochemotherapy should be preferentially used.
c Used alone or in combination with systemic therapies.
Table 8a
Recommendations for first-line treatment of SS.
ECPa Level 3
Chlorambucil þ prednisone Level 3
Systemic therapies in combination with ECP or PUVA
Retinoidsb Level 3
IFN-a Level 3
Low dose MTX Level 4
a ECP can be used alone or in combination with skin directed and
other systemic therapies.
b Including RAR and RXR agonists.
Table 8b
Recommendations for second-line treatment of SS.
Chemotherapy (gemcitabine, pegylated
liposomal doxorubicine, CHOP and CHOP-like
polychemotherapy)
Level 3
Alemtuzumab Level 4
Allogeneic stem cell transplantationa Level 3
a Should be restricted to exceptional patients, see text for details.
Table 9
Agents that can be used for maintenance after remission has been
achieved in MF and SS.a
ECP
IFN-a
Low-dose methotrexate
Mechlorethamine
PUVA
Retinoids
Topical corticosteroids
UVB
a Options are listed alphabetically and should be chosen to be
effective, tolerable, easy to use, and efficient. OCEBM levels are
generally 5.
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may not constitute defence against a claim of negligence,
so deviation from them should not be necessarily
deemed negligence.
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